We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Neutrophil Motility Reveals Potential Sepsis Biomarker

By LabMedica International staff writers
Posted on 21 Dec 2014
The development of sepsis in patients with major burns may be predicted by abnormal motility patterns of white blood cells called neutrophils, measured through the microscopic channels of a novel device.

Since the symptoms of sepsis are similar to those of the systemic inflammation that occurs in almost every serious burn patient, diagnosing sepsis relies on culturing bacteria from the blood, a process that takes 12 to 24 hours. More...


Scientists and bioengineers at the Massachusetts General Hospital (Boston, MA, USA) took blood samples from patients with large thermal injuries admitted to the Massachusetts General Hospital (MGH). Enrolment criteria included burns covering at least 20% of total body surface area, age between 18 and 81, and included in the enrollment were both male and female, proportionally distributed among ethnic groups.

Neutrophils were isolated from whole blood by density gradient using the EasySep Human Neutrophil Kit (STEMCELL Technologies Inc.; Vancouver, BC, Canada). A microfluidic devise was assembled to generate chemical gradients in two simple steps performed at the beginning of the study, after which the device does not require any user intervention or external syringe pumps to operate. The microfluidic devices was made with two layers of photoresist SU8 (Microchem; Newton, MA, USA), the first one 3 µm thin and the second one 50 µm thick, were patterned on one silicon wafer by sequentially employing two photolithography masks and processing cycles. The wafer with patterned photoresist was used as a mold to produce polydimethylsiloxane parts, which were then bonded irreversibly to standard glass slides.

The team analyzed the ability of neutrophils from blood samples of 13 patients with serious burns, collected several times during their treatment, to move through the device when it was primed with one of two chemical attractants or with saline solution, and compared it with the movement of cells from three healthy volunteers. Neutrophils from healthy individuals moved quickly and efficiently through the device toward a chemical attractant, easily navigating around corners and posts, while cells from burn patients showed limited, slower and poorly organized movement toward the chemical signal. This movement of neutrophils in the absence of chemical signals was observed in samples taken from some patients several days before a diagnosis of sepsis could be made, and once effective antibiotic treatment began, the unusual movement pattern began to fade.

Daniel Irimia, MD, PhD, a leading author of the study said, “Since only a handful of rare genetic disorders affect neutrophil function, it has long been assumed that studying these cells was not important; but our findings indicate that neutrophils play a much more important role in sepsis than has been appreciated. We're also working to expand this investigation to other patients at risk for sepsis, to see if the findings from burn patients have broader application.” The study was published on December 9, 2014, in the journal Public Library of Science ONE.

Massachusetts General Hospital
STEMCELL Technologies Inc. 
Microchem

Related Links:

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.